The use of anti-C4d monoclonal antibody as second-line immunotherapy
The medical university from Gdansk is looking for co-development partners and licensees or a commercial agreement with foreign partners for the innovative use of anti-C4d monoclonal antibody as a second-line immunotherapy. It is a technology to accurately identify and eliminate cancer cells that have survived previous treatment with therapeutic antibodies, providing effective support for the treatment of relapsed and refractory cancers.